DETERMINATION OF THE REPRODUCIBILITY OF IMMUNOCHROMATOGRAPHIC TESTS OF DIFFERENT COMPANIES FOR THE SARS-COV-2 VIRUS

2024

Full text Open access: Hybrid Metadata (CSL-JSON)
DOI 10.58318/2957-5702-2023-15-6-16
Data confidence 85 high
How this score is calculated

It is built from checkable properties of the record itself: whether the article has a DOI, how many independent sources confirmed its data, whether the required fields are filled in, and how recent the latest confirmation is. Disagreement between sources and a missing identifier lower it. A value of 80 or above means the record was published without further checking; 60 to 79 means it is published at reduced confidence, with a manual check advisable. A record verified by an editor by hand is never pushed below 90 by a recalculation. This scores our data about the article, not the article itself.

Abstract

COVID-19, formerly coronavirus infection 2019-nCoV is a potentially severe acute respiratory infection caused by the coronavirus SARS-CoV-2 (2019-nCoV). It is a dangerous disease that can occur both in the form of acute respiratory viral infection of mild course and in severe form. The virus is spread by airborne droplets through inhalation of droplets sprayed in the air when coughing, sneezing or talking with the virus, as well as through contact with the virus on the surface, followed by entry into the eyes, nose or mouth. Among the effective measures to combat this dangerous disease is timely and rapid diagnosis. One of the effective means of diagnostic methods is immunochromatographic (IHA) tests, which can be used locally in laboratory and field conditions to diagnose COVID-19 [1-7]. This paper presents the results of a study to determine the sensitivity of IHA tests of different firms. It has been experimentally established that these methods can be effectively used for the diagnosis of COVID-19 in medical institutions.